HOLLAND & KNIGHT LLP for TEVA PHARMACEUTICALS USA, INC.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Drug pricing; Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074); Families First Coronavirus Response Act (H.R. 6201); Coronavirus Aid, Relief, and Economic Security (CARES) Act (H.R. 748).
Foreign entity interest: Teva Pharmaceuticals USA, Inc. is a subsidiary of Teva Pharmaceutical Industries, LTD, headquartered in Israel.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL S. BOCK | — |
| MICHAEL WERNER | — |
Health Issues HCR
Drug Pricing; Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074); Families First Coronavirus Response Act (H.R. 6201); Coronavirus Aid, Relief, and Economic Security (CARES) Act (H.R. 748).
Foreign entity interest: Teva Pharmaceuticals USA, Inc. is a subsidiary of Teva Pharmaceutical Industries, LTD, headquartered in Israel.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL S. BOCK | — |
| MICHAEL WERNER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.